Skip to main content
SpringerLink
Log in

Recent R&D Highlights

  • News & View
  • Published:
Pharmaceutical & Diagnostic Innovation

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study will be published 22 January 2006 in Nature Medicine as an advance online publication.

  2. U.S. Patent No. 6,986,985 entitled ‘Process for Producing Multiple Nucleic Acid Copies in Vivo using a Protein Nucleic Acid Construct’.

  3. Following a Notice of Allowance, the final issuance of a patent involves several administrative steps that typically are completed within 3 months.

  4. The Patent Cooperation Treaty (PCT) is adhered to by about 115 countries and is the result of an effort by many countries to provide some streamlining of patent applications across several countries at once. The Treaty permits an inventor to file a PCT patent application; these are administered by the World Intellectual Property Organization. For an applicant who has filed a patent application in a particular country, a PCT application offers a way to extend the time during which a decision must be made about foreign patent filings, for a longer period than the decision-postponement period provided by the Paris Convention. By filing a PCT application, the applicant can postpone a decision for 30 months.

References

  1. Dana-Farber Cancer Institute. New cellular flaw found in some virulent breast cancers. Media release: 13 Jan 2006

    Google Scholar 

  2. University of Michigan Health System. “Molecular switch” protein protects the heart from major cardiovascular damage. Media release: 19 Jan 2006

    Google Scholar 

  3. Enzo Biochem. Enzo Biochem awarded patent covering processes for producing therapeutic proteins or RNAs in living cells. Media release: 19 Jan 2006

    Google Scholar 

  4. Alnylam. Alnylam announces allowance of U.S. patent broadly covering RNAi therapeutics; patent rights for Tuschl II are held exclusively by Alnylam for development and commercialization of RNAi therapeutics. Media release: 17 Jan 2006

    Google Scholar 

  5. Alethia BioTherapeutics. Alethia BioTherapeutics Inc. announces the filing of a patent application for its bone-related validated targets. Media release: 19 Dec 2005

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Recent R&D Highlights. Pharmaceutical & Diagnostic Innovation 4, 14–15 (2006). https://doi.org/10.1007/BF03257033

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03257033

Search

Navigation